Analyst Ratings For BioDelivery Sciences International, Inc. (NASDAQ:BDSI)
Today, Cantor Fitzgerald set its price target on BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to $5.00 per share.
There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is Buy with a consensus target price of $4.80 per share, a potential 34.45% upside.
Some recent analyst ratings include
- 11/2/2018-BioDelivery Sciences International, Inc. (NASDAQ:BDSI) had its Buy rating reiterated by HC Wainwright with a $5.00 price target
- 1/26/2018-BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has coverage initiated with a Buy ➝ Buy rating and $5.00 price target
- On 12/4/2018 Paolantonio Ernest Robert De, CFO, sold 16,161 with an average share price of $3.79 per share and the total transaction amounting to $61,250.19.
- On 12/3/2018 Francis E Odonnell Jr, Director, sold 8,000 with an average share price of $3.72 per share and the total transaction amounting to $29,760.00.
- On 11/1/2018 Francis E Odonnell Jr, Director, sold 8,000 with an average share price of $3.84 per share and the total transaction amounting to $30,720.00.
- On 10/1/2018 Francis E Odonnell Jr, Director, sold 8,000 with an average share price of $2.75 per share and the total transaction amounting to $22,000.00.
- On 9/13/2018 Francis E Odonnell Jr, Director, sold 151,039 with an average share price of $2.84 per share and the total transaction amounting to $428,950.76.
- On 8/17/2018 Francis E Odonnell Jr, Director, sold 8,000 with an average share price of $2.79 per share and the total transaction amounting to $22,320.00.
- On 4/10/2018 Mark A Sirgo, Director, sold 100,000 with an average share price of $2.06 per share and the total transaction amounting to $206,000.00.
About BioDelivery Sciences International, Inc. (NASDAQ:BDSI)
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.
Recent Trading Activity for BioDelivery Sciences International, Inc. (NASDAQ:BDSI)
Shares of BioDelivery Sciences International, Inc. closed the previous trading session at 3.57 up +0.030 0.85% with 3.6 shares trading hands.